TD 139 is primarily investigated for its potential therapeutic applications in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a galectin-3 inhibitor, targeting the protein involved in the progression of fibrosis. By blocking galectin-3, TD 139 aims to reduce inflammation and fibrosis in affected tissues, offering a promising approach to slow or halt disease progression. Clinical trials are ongoing to evaluate its efficacy and safety in patients with IPF, with the hope of providing a novel treatment option for this challenging condition. Additionally, its mechanism of action suggests potential applications in other fibrotic disorders, such as liver and kidney fibrosis, expanding its therapeutic scope.